Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
1 June 2026PresentationAVZO-021Updated Phase 1/2 (NCT05867251) data at ASCO 2026: monotherapy median PFS reported across doses in HR+/HER2- breast cancer
Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share prices are end-of-day closes, delayed by 24 hours.